New Startup Targets Addiction With GLP-1 Drug

While dozens of companies race to develop the next blockbuster weight loss drug, one new startup is taking GLP-1 medications in a completely different direction.

Baseline Therapeutics launched this week with plans to study GLP-1 drugs as treatments for various substance use disorders. The company represents a major shift in how researchers think about medications originally designed for diabetes and obesity.

GLP-1 drugs like Ozempic and Wegovy have transformed weight management over the past few years. But scientists have noticed something interesting: patients taking these medications often report reduced cravings for alcohol, cigarettes, and other addictive substances.

Now Baseline Therapeutics wants to test whether these observations can translate into real treatments for addiction. The startup joins a small but growing number of researchers exploring whether GLP-1 medications could help people overcome dependencies that have resisted traditional treatments.

More than 46 million Americans struggled with substance use disorders in 2023. Despite decades of research, effective medications remain limited, and relapse rates stay stubbornly high. Many people cycle through treatment programs multiple times without finding lasting help.

The Ripple Effect

If GLP-1 drugs prove effective for addiction, the impact could reach far beyond individual patients. Families torn apart by substance use could find new paths to healing. Emergency rooms overwhelmed by overdoses might see fewer critical cases. Communities devastated by addiction epidemics could begin rebuilding.

The science makes sense too. GLP-1 receptors exist throughout the brain's reward system, the same circuits involved in addiction. Early research suggests these medications might reduce the intense cravings that make recovery so difficult.

Baseline Therapeutics hasn't announced which specific substances it will study first or when clinical trials might begin. But the company's launch signals growing confidence that GLP-1 drugs have applications far beyond their original purpose.

Other research groups have already started exploring this connection. Small studies have shown promising results for alcohol use disorder, and some addiction specialists have begun prescribing GLP-1 medications off-label for patients struggling with various dependencies.

The road from startup launch to approved medication takes years and billions of dollars. Many promising treatments fail in clinical trials. But for people and families affected by addiction, even the possibility of a new tool brings hope where options have been scarce.